InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
1
T+90 hit rate
0%
T+90 mean return
-6.5%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Hunt Hazel, Directeur Scientifique. Officer active across 2 companies, notably Corcept Therapeutics INC. In total, 10 filings have been published. Breakdown: 0 buy · 1 sell. Total volume traded: €579k. Activity tracked since 14 July 2021. The latest transaction was filed on 11 February 2025 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Declarations10 total
150,000 shares@ US$3.2926.1% of flowCommon StockSEC:0000950170-25-020219:0
60,000 shares@ US$2.818.5% of flowCommon StockSEC:0000950170-24-091049:0
50,000 shares@ US$3.027.5% of flowCommon StockSEC:0000950170-24-004343:0
20,455 shares@ US$30.88531.5% of flowCommon StockSEC:0000950170-23-042785:0
50,000 shares@ US$3.027.5% of flowCommon StockSEC:0000950170-23-040803:0
50,000 shares@ US$2.085.8% of flowCommon StockSEC:0000899243-22-032305:0
40,000 shares@ US$3.320.0019% mcap49.0% of flowCommon StockSEC:0000899243-22-003573:0
40,000 shares@ US$3.3249.0% of flowCommon StockSEC:0000899243-22-003573
50,000 shares@ US$2.8951.0% of flowCommon StockSEC:0000899243-21-028678
50,000 shares@ US$2.890.0020% mcap51.0% of flowCommon StockSEC:0000899243-21-028678:0
10 of 10 declarations
About Hunt Hazel
Hazel Hunt is the Chief Scientific Officer at Corcept Therapeutics Inc. In this role, she is responsible for leading research and the development of new treatments. Her scientific expertise is essential for innovation within the company.
